{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:42Z","timestamp":1793424762784,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502170"],"award-info":[{"award-number":["82502170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Medical Science Research Foundation of Zhejiang Province","award":["2024KY1252"],"award-info":[{"award-number":["2024KY1252"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10067-026-08407-1","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T06:52:44Z","timestamp":1789282364000},"page":"6607-6619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus"],"prefix":"10.1007","volume":"45","author":[{"given":"Feiping","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaolan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-5351","authenticated-orcid":false,"given":"Jianxin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"issue":"2","key":"8407_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/BOR.0000000000000480","volume":"30","author":"G Stojan","year":"2018","unstructured":"Stojan G, Petri M (2018) Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol 30(2):144\u2013150","journal-title":"Curr Opin Rheumatol"},{"issue":"22","key":"8407_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110\u20132121","journal-title":"N Engl J Med"},{"issue":"10188","key":"8407_CR3","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","volume":"393","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393(10188):2344\u20132358","journal-title":"Lancet"},{"issue":"10","key":"8407_CR4","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1136\/ard-2024-225617","volume":"83","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis A, Kostopoulou M, Bertsias G, Boumpas DT (2023) Response to: correspondence on \u2018EULAR recommendations for the management of systemic lupus erythematosus: 2023 update\u2019 by Fanouriakis et al. Ann Rheum Dis 83(10):e19","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8407_CR5","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75(9):1615\u20131621","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8407_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2017-211613","volume":"77","author":"M Zen","year":"2018","unstructured":"Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A et al (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77(1):104\u2013110","journal-title":"Ann Rheum Dis"},{"key":"8407_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623944","volume":"11","author":"NR Jog","year":"2020","unstructured":"Jog NR, James JA (2020) Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol 11:623944","journal-title":"Front Immunol"},{"issue":"20","key":"8407_CR8","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N (2022) Epstein-Barr virus: biology and clinical disease. Cell 185(20):3652\u20133670","journal-title":"Cell"},{"key":"8407_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317753069","author":"L Han","year":"2018","unstructured":"Han L, Zhang Y, Wang Q, Xin M, Yang K, Lei K et al (2018) Epstein-Barr virus infection and type I interferon signature in patients with systemic lupus erythematosus. Lupus. https:\/\/doi.org\/10.1177\/0961203317753069","journal-title":"Lupus"},{"issue":"2","key":"8407_CR10","first-page":"523","volume":"18","author":"A Piroozmand","year":"2017","unstructured":"Piroozmand A, Haddad Kashani H, Zamani B (2017) Correlation between Epstein-Barr virus infection and disease activity of systemic lupus erythematosus: a cross-sectional study. Asian Pac J Cancer Prev 18(2):523\u2013527","journal-title":"Asian Pac J Cancer Prev"},{"key":"8407_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1307589","volume":"14","author":"A Banko","year":"2023","unstructured":"Banko A, Cirkovic A, Miskovic R, Jeremic I, Grk M, Basaric M et al (2023) Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus. Front Immunol 14:1307589","journal-title":"Front Immunol"},{"issue":"10","key":"8407_CR12","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/rheumatology\/kead673","volume":"63","author":"L Hu","year":"2024","unstructured":"Hu L, Tu J, Gui J, Fang M, Sun L (2024) Landscape of immune cells in systematic lupus erythematosus patients with Epstein-Barr virus infection: assessed by single-cell sequencing. Rheumatology (Oxford) 63(10):2856\u20132864","journal-title":"Rheumatology (Oxford)"},{"key":"8407_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100117","volume":"4","author":"RA Wood","year":"2021","unstructured":"Wood RA, Guthridge L, Thurmond E, Guthridge CJ, Kheir JM, Bourn RL et al (2021) Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmun 4:100117","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"8407_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1128\/JVI.79.2.1296-1307.2005","volume":"79","author":"LL Laichalk","year":"2005","unstructured":"Laichalk LL, Thorley-Lawson DA (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79(2):1296\u20131307","journal-title":"J Virol"},{"issue":"4","key":"8407_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u201387","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"8407_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F et al (2025) A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med 393(15):1475\u201385","journal-title":"N Engl J Med"},{"key":"8407_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587380","volume":"11","author":"G Houen","year":"2020","unstructured":"Houen G, Trier NH (2020) Epstein-Barr virus and systemic autoimmune diseases. Front Immunol 11:587380","journal-title":"Front Immunol"},{"issue":"4","key":"8407_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2353\/jmoldx.2008.080023","volume":"10","author":"ML Gulley","year":"2008","unstructured":"Gulley ML, Tang W (2008) Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 10(4):279\u2013292","journal-title":"J Mol Diagn"},{"issue":"1","key":"8407_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5501\/wjv.v1.i1.31","volume":"1","author":"M De Paschale","year":"2012","unstructured":"De Paschale M, Clerici P (2012) Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol 1(1):31\u201343","journal-title":"World J Virol"},{"issue":"4","key":"8407_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CMR.00046-17","volume":"30","author":"J Sakai","year":"2017","unstructured":"Sakai J, Akkoyunlu M (2017) The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev 30(4):991\u20131014","journal-title":"Clin Microbiol Rev"},{"issue":"824","key":"8407_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady0210","volume":"17","author":"S Younis","year":"2025","unstructured":"Younis S, Moutusy SI, Rasouli S, Jahanbani S, Pandit M, Wu X et al (2025) Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus. Sci Transl Med 17(824):eady0210","journal-title":"Sci Transl Med"},{"issue":"6","key":"8407_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, Mackay F (2014) The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10(6):365\u2013373","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"8407_CR23","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A et al (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 64(7):2328\u201337","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8407_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02338-23","volume":"14","author":"B Mitra","year":"2023","unstructured":"Mitra B, Beri NR, Guo R, Burton EM, Murray-Nerger LA, Gewurz BE (2023) Characterization of target gene regulation by the two Epstein-Barr virus oncogene LMP1 domains essential for B-cell transformation. MBio 14(6):e02338-23","journal-title":"MBio"},{"issue":"7","key":"8407_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491\u2013502","journal-title":"Nat Rev Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08407-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:05:39Z","timestamp":1793423139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08407-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8407"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08407-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board (IRB) of the First Affiliated Hospital of Wenzhou Medical University and was conducted in accordance with the Declaration of Helsinki (YJ-2023\u2013052-JZ-01). Given the retrospective design, written informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}